GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Total Current Liabilities

BioVaxys Technology (BioVaxys Technology) Total Current Liabilities : $1.54 Mil (As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. BioVaxys Technology's total current liabilities for the quarter that ended in Jul. 2023 was $1.54

BioVaxys Technology Total Current Liabilities Historical Data

The historical data trend for BioVaxys Technology's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Total Current Liabilities Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22
Total Current Liabilities
0.14 0.09 0.68 0.26 1.20

BioVaxys Technology Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 1.20 1.40 1.30 1.54

BioVaxys Technology Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

BioVaxys Technology's Total Current Liabilities for the fiscal year that ended in Oct. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.197+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=1.20

BioVaxys Technology's Total Current Liabilities for the quarter that ended in Jul. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.542+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=1.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

BioVaxys Technology Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Total Current Liabilities
Comparable Companies
XCNQ:NOVA XCNQ:GLOW XCNQ:BRAX XCNQ:MBIO TSX:APLI TSXV:IOT XCNQ:MESC TSXV:MRVL TSX:IPCI XCNQ:CMND OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
5LB:Germany BIOV:Canada
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
Website
https://www.biovaxys.com
BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.